Stanford University
Showing 31,051-31,100 of 36,175 Results
-
Nicholas Telischak, MD, MS
Clinical Associate Professor, Radiology
Clinical Associate Professor (By courtesy), NeurosurgeryBioA native of the Bay Area, Dr. Nick Telischak is a dual fellowship-trained neurointerventional surgeon and neuroradiologist at Stanford Health Care. With board certifications in radiology and neuroradiology, he serves as a clinical associate professor in the Department of Radiology, and, by courtesy of the Department of Neurosurgery, at Stanford School of Medicine.
Dr. Telischak specializes in diagnosing and treating artery disorders in the brain and spine, including brain aneurysms, arteriovenous malformations (AVM), and dural arteriovenous fistula (dAVF), and stroke. Dr. Telischak also specializes in venous disorders in the brain including idiopathic intracranial hypertension (IIH). He also has a special interest in pulsatile tinnitus, a whooshing sound in the ears that occurs in rhythm with the heartbeat. Dr. Telischak also treats painful spinal (vertebral) fractures, spinal metastases (tumors resulting from cancer elsewhere in the body), and congenital vascular malformations (blood vessel abnormalities that are present at birth). He treats these conditions using minimally invasive, image-guided procedures and state-of-the-art technology.
Prior to joining Stanford Health Care, Dr. Telischak helped develop the Stroke Program at California Pacific Medical Center and Mills-Peninsula Medical Center, giving him a broad perspective on medical care systems within the Bay Area.
Dr. Telischak’s research focuses on:
• Identifying biomarkers to diagnose large vessel occlusion stroke (stroke in one of the large arteries in the brain)
• Noninvasive MRI techniques for diagnosing idiopathic intracranial hypertension (high pressure within the skull)
He is also the principal investigator for a study examining the efficacy of vertebroplasty and kyphoplasty for the treatment of painful vertebral compression fractures.
In addition, Dr. Telischak holds a master’s degree in bioengineering. He has worked with several companies pioneering new devices to treat brain aneurysms, vascular malformations, and strokes caused by blood clots, as well as new treatments for venous disorders in the brain caused by idiopathic intracranial hypertension.
Dr. Telischak has published more than 20 peer-reviewed articles and has been invited to present locally, nationally, and internationally at meetings for the Society of NeuroInterventional Surgery, American Society of Neuroradiology, and Jornada de Stroke in Asuncion, Paraguay, where he has served as visiting faculty. -
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Kharis Templeman
Hoover Institution Research Fellow
Current Research and Scholarly InterestsHis current research agenda includes work on China’s Taiwan policy, the drivers of defense spending in Taiwan, and Taiwan’s party system evolution after the transition to democracy.
-
Joyce Teng, MD, PhD
Professor of Dermatology and, by courtesy, of Pediatrics
BioJoyce Teng, MD, PhD is a professor in dermatology at Stanford University. She is affiliated with multiple hospitals in the area, including Lucile Salter Packard Children's Hospital (LPCH) at Stanford and Stanford Hospital and Clinics (SHC). She received her medical degree from Vanderbilt University School of Medicine and has been in practice for more than 12 years. She is one of the 6 pediatric dermatologists practicing at LPCH and one of 72 at SHC who specialize in Dermatology. She sees patients with rare genetic disorders, birthmarks, vascular anomalies and a variety of inflammatory skin diseases. She is also an experienced pediatric dermatological surgeon. Her research interests are drug discovery and novel therapy for skin disorders.
-
Nelson Teng
Professor of Obstetrics and Gynecology (Oncology), Emeritus
Current Research and Scholarly InterestsGynecologic Malignancies
Immunotherapy
Biologic Response Modifiers
New Drug Development
Antigenic specificities of human antibodies encoded by the VH4-34 gene -
Valerie Teng
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Valerie Teng is a board certified family physician with special interests in preventative medicine and women's health. Her experiences in caring for patients with chronic conditions, such as diabetes and hypertension, have fueled her desire to partner with patients to enter healthier lifestyles. She is also passionate about providing comprehensive care to patients of all ages, including newborns and teens.
During her residency training, Dr. Teng explored many opportunities in medical education through the O’Connor-Stanford Leaders in Education Residency (OSLER) program. She is delighted to continue in medical education as a part of the faculty at Stanford Family Medicine. -
Azusa Terasaki
Postdoctoral Scholar, Pathology
BioAzusa Terasaki, MD, PhD, is a Postdoctoral scholar in the Department of Pathology at Stanford University School of Medicine. Her research focuses on tumor immunology and cancer metabolism, with a particular interest in mitochondrial transfer between cancer and immune cells and its role in immune suppression and metastasis.
Dr. Terasaki received her medical degree and PhD in Japan, where she completed her surgical training and is a board-certified surgeon with additional certifications as a breast specialist and in cancer therapy. During her clinical career, she developed a strong interest in translational research that bridges fundamental discoveries and patient care.
Her current work investigates how cancer cells reprogram immune cells through organelle transfer, integrating imaging, flow cytometry, and multi-omic approaches to uncover novel mechanisms of tumor–immune interaction. Her goal is to identify new therapeutic targets and biomarkers to improve cancer treatment outcomes.
